73MO Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study

Kim, Y.J.; Kurosaki, M.; Numata, K.; Lim, H.Y.; Ikeda, M.; Kudo, M.; Yh, Huang; Shao, G.; Kato, N.; Kim, Doyoung; Cho, S-B.; Hsu, Chao‐Ping; Shen, Lin; Jeng, Long-Bin; Kk, Kuo; Mao, Y.; Chewaskulyong, B.; Khan, J.; Ozgurdal, K.; Qin, S.

doi:10.1016/j.annonc.2022.10.109

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median PFS in the regorafenib monotherapy group (3.2 months) was consistent with the REFINE study (3.9 months). The median OS in the regorafenib monotherapy group (16.4 months) was longer than the overall population in the REFINE study (13.2 months), but was similar to patients from Asia (15.0 months) and patients with Child‐Pugh A(15.5 months) 22 . Together with the REFINE study, our study once again confirmed the efficacy of regorafenib as second‐line therapy for advanced HCC in real‐world settings.…”

Section: Discussionsupporting

confidence: 77%

“…Median PFS and OS were also significantly improved in the regorafenib plus with Child-Pugh A(15.5 months). 22 Together with the REFINE study, our study once again confirmed the efficacy of regorafenib as second-line therapy for advanced HCC in real-world settings. In our real-world study, physicians would employ locoregional treatment modalities, including transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC), after considering liver function and tumor burden.…”

Section: Discussionsupporting

confidence: 72%

See 1 more Smart Citation

Regorafenib with immunotherapy versus regorafenib alone as second‐line treatment for hepatocellular carcinoma: A multicenter real‐world study

Qiao,

He,

Wang

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

IntroductionRegorafenib remains the standard and widely used second‐line strategy for advanced hepatocellular carcinoma (HCC). There is still a lack of large‐scale multicenter real‐world evidence concerning the concurrent use of regorafenib with immune checkpoint inhibitors (ICI). This study aims to evaluate whether combining regorafenib with ICI provides greater clinical benefit than regorafenib monotherapy as second‐line therapy for advanced HCC under real‐world circumstances.Patients and MethodsThe study included 208 patients from five medical facilities. One hundred forty‐three patients received regorafenib plus ICI combination therapy, while 65 patients received regorafenib monotherapy. Propensity score matching (PSM) analysis was employed.ResultsThe regorafenib plus ICI group demonstrated significantly higher objective response rate (24.3% vs. 10.3%, after PSM, p = 0.030) and disease control rate (79.4% vs. 50.0%, after PSM, p < 0.001) compared to the regorafenib monotherapy group based on mRECIST criteria. Median progression‐free survival (7.9 vs. 3.2 months, after PSM, p < 0.001) and overall survival (25.6 vs. 16.4 months, p = 0.010, after PSM) were also considerably longer in the regorafenib plus ICI group. The incidence of Grades 3–4 treatment‐related adverse events (TRAEs) was marginally greater in the regorafenib plus ICI group than in the regorafenib group (23.8% vs. 20.0%, p = 0.546). Notably, there were no instances of treatment‐related mortality or emergence of new TRAEs in any treatment group.ConclusionThe combination of regorafenib and ICI shows potential as a viable second‐line treatment for advanced HCC, exhibiting favorable efficacy while maintaining a tolerable safety profile in contrast to regorafenib monotherapy.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionsupporting

confidence: 72%